OncoTherics CEO Stefan Ogrodzinski will present the company’s latest news at the LSBC Central European Life Science Investment Conference, taking place at Hotel Stary in Krakow, Poland, from 21–23 October 2026.

OncoTherics will participate in the company presentations on 23 October, sharing an update on the business, its development priorities and investment opportunity with investors and life science industry leaders.

The company is developing therapeutics designed to target treatment-resistant cancer cells in low-oxygen regions of tumours. Its programmes include AQ4N, its lead clinical programme in newly diagnosed glioblastoma, and OCT1002, a second-generation asset in advanced preclinical development. Learn more about our programmes.

We look forward to meeting fellow delegates and discussing opportunities for investment and collaboration to support the next stage of OncoTherics’ development.

To arrange a meeting during the conference, please contact enquiry@oncotherics.com.